Spyre Therapeutics's total assets for Q3 2025 were $504.60M, a decrease of -6.35% from the previous quarter. SYRE total liabilities were $49.50M for the fiscal quarter, a -40.40% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.